{"id":"https://openalex.org/W3205631367","doi":"https://doi.org/10.1186/s13223-021-00610-w","title":"The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada","display_name":"The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada","publication_year":2021,"publication_date":"2021-10-12","ids":{"openalex":"https://openalex.org/W3205631367","doi":"https://doi.org/10.1186/s13223-021-00610-w","mag":"3205631367","pmid":"https://pubmed.ncbi.nlm.nih.gov/34641954","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8507225"},"language":"en","primary_location":{"id":"doi:10.1186/s13223-021-00610-w","doi":"https://doi.org/10.1186/s13223-021-00610-w","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s13223-021-00610-w","pdf_url":"https://aacijournal.biomedcentral.com/track/pdf/10.1186/s13223-021-00610-w","source":{"id":"https://openalex.org/S658968","display_name":"Allergy Asthma and Clinical Immunology","issn_l":"1710-1484","issn":["1710-1484","1710-1492"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Allergy, Asthma & Clinical Immunology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacijournal.biomedcentral.com/track/pdf/10.1186/s13223-021-00610-w","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5022928428","display_name":"Mohsen Sadatsafavi","orcid":"https://orcid.org/0000-0002-0419-7862","observed_orcids":["https://orcid.org/0000-0002-0419-7862"]},"institutions":[{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"Mohsen Sadatsafavi","raw_affiliation_strings":["Respiratory Evaluation Sciences Program, Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V6T1Z3, Canada. msafavi@mail.ubc.ca","Respiratory Evaluation Sciences Program, Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V6T1Z3, Canada"],"raw_orcid":"https://orcid.org/0000-0002-0419-7862","affiliations":[{"raw_affiliation_string":"Respiratory Evaluation Sciences Program, Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V6T1Z3, Canada. msafavi@mail.ubc.ca","institution_ids":["https://openalex.org/I141945490"]},{"raw_affiliation_string":"Respiratory Evaluation Sciences Program, Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V6T1Z3, Canada","institution_ids":["https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101642543","display_name":"J. Mark FitzGerald","orcid":"https://orcid.org/0000-0002-8753-6056","observed_orcids":["https://orcid.org/0000-0002-8753-6056"]},"institutions":[{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]},{"id":"https://openalex.org/I4210150180","display_name":"Vancouver Coastal Health Research Institute","ror":"https://ror.org/04htzww22","country_code":"CA","type":"facility","lineage":["https://openalex.org/I141074466","https://openalex.org/I4210150180"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"J. Mark FitzGerald","raw_affiliation_strings":["Centre for Lung Health, Vancouver Coastal Health Research Institute, University of British Columbia, 2775 Laurel Street, Vancouver, BC, V5Z1M9, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre for Lung Health, Vancouver Coastal Health Research Institute, University of British Columbia, 2775 Laurel Street, Vancouver, BC, V5Z1M9, Canada","institution_ids":["https://openalex.org/I141945490","https://openalex.org/I4210150180"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026242254","display_name":"Paul M. O\u2019Byrne","orcid":"https://orcid.org/0000-0003-0979-281X","observed_orcids":["https://orcid.org/0000-0003-0979-281X"]},"institutions":[{"id":"https://openalex.org/I98251732","display_name":"McMaster University","ror":"https://ror.org/02fa3aq29","country_code":"CA","type":"education","lineage":["https://openalex.org/I98251732"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Paul M. O\u2019Byrne","raw_affiliation_strings":["Firestone Institute of Respiratory Health, St Joseph\u2019s Healthcare and Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, 1280 Main Street West, Health Science Center, 3W10, Hamilton, ON, L8S 4K2, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Firestone Institute of Respiratory Health, St Joseph\u2019s Healthcare and Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, 1280 Main Street West, Health Science Center, 3W10, Hamilton, ON, L8S 4K2, Canada","institution_ids":["https://openalex.org/I98251732"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059987874","display_name":"Mena Soliman","orcid":"https://orcid.org/0000-0003-4066-1535","observed_orcids":["https://orcid.org/0000-0003-4066-1535"]},"institutions":[{"id":"https://openalex.org/I4210149652","display_name":"AstraZeneca (Canada)","ror":"https://ror.org/04n8fbz89","country_code":"CA","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210149652"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Mena Soliman","raw_affiliation_strings":["Medical Affairs, AstraZeneca, 1004 Middlegate Road, Mississauga, ON, L4Y 1M4, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Affairs, AstraZeneca, 1004 Middlegate Road, Mississauga, ON, L4Y 1M4, Canada","institution_ids":["https://openalex.org/I4210149652"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045152912","display_name":"Niroshan Sriskandarajah","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210149652","display_name":"AstraZeneca (Canada)","ror":"https://ror.org/04n8fbz89","country_code":"CA","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210149652"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Niroshan Sriskandarajah","raw_affiliation_strings":["Market Access, AstraZeneca, 1004 Middlegate Road, Mississauga, ON, L4Y 1M4, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Market Access, AstraZeneca, 1004 Middlegate Road, Mississauga, ON, L4Y 1M4, Canada","institution_ids":["https://openalex.org/I4210149652"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067553502","display_name":"Colin Vicente","orcid":"https://orcid.org/0000-0002-2940-1743","observed_orcids":["https://orcid.org/0000-0002-2940-1743"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Colin Vicente","raw_affiliation_strings":["PIVINA Consulting Inc., 2600 Skymark Avenue, Suite 11-202, Mississauga, ON, L4W 5B2, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PIVINA Consulting Inc., 2600 Skymark Avenue, Suite 11-202, Mississauga, ON, L4W 5B2, Canada","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5023192416","display_name":"Sarowar Muhammad Golam","orcid":"https://orcid.org/0009-0002-1590-5542","observed_orcids":["https://orcid.org/0009-0002-1590-5542"]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Sarowar Muhammad Golam","raw_affiliation_strings":["Global Market Access and Pricing, BioPharmaceuticals R&D, AstraZeneca, M\u00f6lndal, 431 83, Gothenburg, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Market Access and Pricing, BioPharmaceuticals R&D, AstraZeneca, M\u00f6lndal, 431 83, Gothenburg, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5022928428"],"corresponding_institution_ids":["https://openalex.org/I141945490"],"apc_list":{"value":2590,"currency":"USD","value_usd":2590},"apc_paid":{"value":2590,"currency":"USD","value_usd":2590},"fwci":1.8592,"has_fulltext":true,"cited_by_count":19,"citation_normalized_percentile":{"value":0.85041383,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"17","issue":"1","first_page":"108","last_page":"108"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.6342999935150146,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.6342999935150146,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.3555000126361847,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10143","display_name":"Chronic Obstructive Pulmonary Disease (COPD) Research","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mild-asthma","display_name":"mild asthma","score":0.7720000147819519},{"id":"https://openalex.org/keywords/short-acting-beta-agonists","display_name":"short-acting beta2-agonists","score":0.7760000228881836},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8550000190734863},{"id":"https://openalex.org/keywords/asthma-exacerbations","display_name":"asthma exacerbations","score":0.7870000004768372},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.8090000152587891},{"id":"https://openalex.org/keywords/terbutaline","display_name":"terbutaline","score":0.7200000286102295},{"id":"https://openalex.org/keywords/asthma-controller-therapy","display_name":"asthma controller therapy","score":0.6259999871253967},{"id":"https://openalex.org/keywords/health-care-utilization","display_name":"health care utilization","score":0.5659999847412109},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6110000014305115},{"id":"https://openalex.org/keywords/global-initiative-for-asthma","display_name":"Global Initiative for Asthma","score":0.765999972820282}],"concepts":[{"id":"https://openalex.org/C2776136866","wikidata":"https://www.wikidata.org/wiki/Q422212","display_name":"Budesonide","level":3,"score":0.9026939272880554},{"id":"https://openalex.org/C2779871671","wikidata":"https://www.wikidata.org/wiki/Q637247","display_name":"Formoterol","level":4,"score":0.8402001857757568},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7676005363464355},{"id":"https://openalex.org/C2776042228","wikidata":"https://www.wikidata.org/wiki/Q35869","display_name":"Asthma","level":2,"score":0.7657254338264465},{"id":"https://openalex.org/C2776804153","wikidata":"https://www.wikidata.org/wiki/Q210420","display_name":"Corticosteroid","level":2,"score":0.7508085370063782},{"id":"https://openalex.org/C2777450039","wikidata":"https://www.wikidata.org/wiki/Q637247","display_name":"Budesonide/formoterol","level":5,"score":0.5236403942108154},{"id":"https://openalex.org/C2778283404","wikidata":"https://www.wikidata.org/wiki/Q6736822","display_name":"Maintenance therapy","level":3,"score":0.45987409353256226},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.4279361665248871},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2098182737827301},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.08901065587997437}],"mesh":[],"locations_count":5,"locations":[{"id":"doi:10.1186/s13223-021-00610-w","doi":"https://doi.org/10.1186/s13223-021-00610-w","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s13223-021-00610-w","pdf_url":"https://aacijournal.biomedcentral.com/track/pdf/10.1186/s13223-021-00610-w","source":{"id":"https://openalex.org/S658968","display_name":"Allergy Asthma and Clinical Immunology","issn_l":"1710-1484","issn":["1710-1484","1710-1492"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Allergy, Asthma & Clinical Immunology","raw_type":"journal-article"},{"id":"pmid:34641954","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34641954","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8507225","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8507225/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Allergy Asthma Clin Immunol","raw_type":"Text"},{"id":"pmh:oai:circle.library.ubc.ca:2429/80193","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/2429/80193","pdf_url":null,"source":{"id":"https://openalex.org/S4377196297","display_name":"cIRcle (University of British Columbia)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I141945490","host_organization_name":"University of British Columbia","host_organization_lineage":["https://openalex.org/I141945490"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:c4b094a1c11345eda39bfce98150ac78","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/c4b094a1c11345eda39bfce98150ac78","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Allergy, Asthma & Clinical Immunology, Vol 17, Iss 1, Pp 1-13 (2021)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1186/s13223-021-00610-w","doi":"https://doi.org/10.1186/s13223-021-00610-w","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s13223-021-00610-w","pdf_url":"https://aacijournal.biomedcentral.com/track/pdf/10.1186/s13223-021-00610-w","source":{"id":"https://openalex.org/S658968","display_name":"Allergy Asthma and Clinical Immunology","issn_l":"1710-1484","issn":["1710-1484","1710-1492"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Allergy, Asthma & Clinical Immunology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3205631367.pdf","grobid_xml":"https://content.openalex.org/works/W3205631367.grobid-xml"},"referenced_works_count":41,"referenced_works":["https://openalex.org/W161823661","https://openalex.org/W387031605","https://openalex.org/W1970708453","https://openalex.org/W1994623641","https://openalex.org/W1996417170","https://openalex.org/W2014545680","https://openalex.org/W2021351287","https://openalex.org/W2030556594","https://openalex.org/W2049632078","https://openalex.org/W2062076030","https://openalex.org/W2085902327","https://openalex.org/W2119771117","https://openalex.org/W2128911553","https://openalex.org/W2137334142","https://openalex.org/W2141024340","https://openalex.org/W2141896850","https://openalex.org/W2144317367","https://openalex.org/W2145753781","https://openalex.org/W2166394031","https://openalex.org/W2199584453","https://openalex.org/W2487414582","https://openalex.org/W2601675613","https://openalex.org/W2746827280","https://openalex.org/W2753097505","https://openalex.org/W2789889042","https://openalex.org/W2796156341","https://openalex.org/W2804556773","https://openalex.org/W2804974483","https://openalex.org/W2914185992","https://openalex.org/W2946771756","https://openalex.org/W2954327547","https://openalex.org/W2969375889","https://openalex.org/W2979920017","https://openalex.org/W2999425512","https://openalex.org/W3000986384","https://openalex.org/W3038582849","https://openalex.org/W3096362429","https://openalex.org/W3097380983","https://openalex.org/W3097387385","https://openalex.org/W3128420623","https://openalex.org/W3131215500"],"related_works":["https://openalex.org/W3038582849","https://openalex.org/W4200053518","https://openalex.org/W2989948934","https://openalex.org/W4414612421","https://openalex.org/W6958596442","https://openalex.org/W3198907428","https://openalex.org/W3195107594","https://openalex.org/W2273651304","https://openalex.org/W2107614418","https://openalex.org/W4401046636"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"The":[2,107],"Global":[3],"Initiative":[4],"for":[5,21,303],"Asthma":[6],"recommends":[7],"the":[8,35,49,205,208,214,219,288,304,310,313],"use":[9,120],"of":[10,41,51,143,167,207,226,236,254,264,306,312],"as-needed":[11,42,52,59,88,102,243,257,272,323],"low-dose":[12,55,239,319],"inhaled":[13],"corticosteroid":[14],"(ICS)-formoterol":[15],"as":[16],"a":[17,129,135,140,246,251,260,300],"preferred":[18],"controller":[19],"therapy":[20,98],"patients":[22,64],"with":[23,65,134,268,318],"mild":[24,66,307],"asthma.":[25,67],"These":[26],"recommendations":[27],"were":[28,161,182,201],"based,":[29],"in":[30,63,156,178,218,291],"part,":[31],"on":[32,151,184],"evidence":[33],"from":[34,122,128,153,163,309],"SYGMA":[36,123,154,164],"1":[37,155],"and":[38,84,117,125,139,171,175,197,230,282,293],"2":[39,165],"studies":[40],"budesonide-formoterol.":[43],"This":[44],"analysis":[45,110],"aimed":[46],"to":[47,54,86,92,203],"compare":[48,87],"cost-effectiveness":[50],"budesonide-formoterol":[53,89,212,258,286,298],"maintenance":[56,97,240,269,320],"ICS":[57,241,270,321],"plus":[58,101,242,271,322],"short-acting":[60],"\u03b22-agonist":[61],"(SABA)":[62],"Methods":[68],"A":[69],"Markov":[70],"cohort":[71],"model":[72],"was":[73,126,149,213,275],"designed":[74],"that":[75],"included":[76],"three":[77],"possible":[78],"health":[79],"states":[80],"(non-exacerbation,":[81],"severe":[82,112],"exacerbation,":[83,113],"death)":[85],"200\u20136":[90],"\u03bcg":[91,96],"twice-daily":[93],"budesonide":[94],"200":[95],"(low-dose":[99],"ICS)":[100],"terbutaline":[103],"0.5":[104],"mg":[105],"(SABA).":[106],"deterministic":[108,193],"base-case":[109,220],"used":[111],"adverse":[114],"event":[115],"(AE),":[116],"healthcare":[118],"resource":[119],"data":[121,152],"2,":[124],"conducted":[127,202],"Canadian":[130,180,314],"public":[131,315],"payer":[132,316],"perspective":[133,311],"50-year":[136,247],"time":[137,248],"horizon,":[138],"discount":[141],"rate":[142],"1.5%":[144],"per":[145,228],"annum.":[146],"Moderate":[147],"exacerbation":[148],"modelled":[150],"sensitivity":[157,292],"analyses.":[158,295],"Utility":[159],"values":[160,189],"derived":[162],"quality":[166],"life":[168,232],"data.":[169],"All-cause-":[170],"asthma-related":[172],"mortality":[173],"rates":[174],"costs":[176],"(reported":[177],"2019":[179],"dollars)":[181],"based":[183],"published":[185],"data,":[186],"using":[187],"Canada-specific":[188],"where":[190],"available.":[191],"One-way":[192],"sensitivity,":[194,196],"probabilistic":[195],"eight":[198],"scenario":[199,294],"analyses":[200],"examine":[204],"robustness":[206],"results.":[209],"Results":[210],"As-needed":[211,285,297],"dominant":[215,289],"treatment":[216,290,305],"option":[217,302],"analysis,":[221],"providing":[222],"incremental":[223],"cost":[224],"savings":[225],"$9882":[227],"patient":[229],"quality-adjusted":[231],"year":[233],"(QALY)":[234],"gains":[235],"0.002":[237],"versus":[238],"SABA":[244],"over":[245],"horizon.":[249],"Using":[250],"willingness-to-pay":[252],"threshold":[253],"$50,000/QALY":[255],"($100,000/QALY),":[256],"had":[259],"94%":[261],"(95%)":[262],"probability":[263],"being":[265],"cost-effective":[266],"compared":[267,317],"SABA.":[273,324],"Cost-saving":[274],"mostly":[276],"driven":[277],"by":[278],"lower":[279],"overall":[280],"medication":[281],"AE-related":[283],"costs.":[284],"remained":[287],"Conclusions":[296],"is":[299],"cost-saving":[301],"asthma":[308]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":3}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2021-10-25T00:00:00"}